Trial Profile

Survival of advanced Non Small Cells Lung Cancer patients treated with EGF therapeutic vaccine compared with conventional treatment.

Status: Suspended

Phase of Trial: Phase III

Latest Information Update: 14 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BV NSCLC 001 (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

29 Feb 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
24 Oct 2013 New source identified and integrated: Cuban Clinical Trial Registry record.
27 Jun 2012 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com